This compound is primarily utilized in the pharmaceutical industry as a chiral building block for the synthesis of active pharmaceutical ingredients (APIs). Its structure, featuring a difluoromethoxy group and a chiral amine, makes it valuable in the development of drugs targeting central nervous system disorders, such as depression, anxiety, and neurodegenerative diseases. The difluoromethoxy group enhances the metabolic stability and bioavailability of the resulting compounds, while the chiral center allows for the creation of enantiomerically pure drugs, which can improve efficacy and reduce side effects. Additionally, it is explored in the development of enzyme inhibitors and receptor modulators due to its ability to interact selectively with biological targets.